|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/12/2012 8:44:53 AM
People who abuse the prescription pain drug Opana ER by injecting it into their bloodstream risk developing a serious blood disorder that could result in kidney failure or death, U.S. health regulators warned on Thursday. Opana, a powerful opioid painkiller containing oxymorphone, is produced by Endo Pharmaceuticals. The blood disorder, thrombotic thrombocytopenic purpura, resulted in kidney failure requiring dialysis in some cases and at least one death, the Food and Drug Administration said. The disorder causes clots to form in small blood vessels throughout the body, limiting or blocking blood flow to the organs. Platelets, a certain type of blood cell, help the clotting process. When this disorder occurs, however, platelets clump together in the blood clots, making fewer platelets available in the blood in other parts of the body to help clotting there. This can lead to bleeding under the skin and purple-colored spots called purpura, or to bleeding inside the body. Thrombotic thrombocytopenic purpura can cause death or lead to other complications with permanent damage, including brain damage and stroke, in addition to kidney failure.
|
|
|
|
|
|
|
|
|
|
|